CompletedNCT01010776
Paliperidone extended-release after risperidone for schizophrenia
About this title
A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone
Read the official source — NCT01010776Medication studyAges 18–60Brazil
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Belo Horizonte and 9 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateFebruary 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 223
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Brazil
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01010776
- Official title
Show the full official title
A Study to Evaluate Switching From Risperidone to Paliperidone ER (Extended Release) in the Treatment of Stable But Symptomatic Schizophrenia Outpatients: Patients Satisfaction and Quality of Life
Get this study by email
Recruitment & locations
CompletedBelo Horizonte · Criciúma · Curitiba
7 more locations
- Goiânia
- Itapira
- Marília
- Rio de Janeiro
- Salvador
- São Paulo
- Sorocaba
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag Farmaceutica Ltda.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone Extended Release (ER).
Who was this study for?
Listed age limits: 18 years to 60 years.
